G1 THERAPEUTICS IN

G1 Therapeutics (www.g1therapeutics.com/), Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Its lead clinical compound Trilaciclib, is a therapy designed to improve outcomes for patients who are treated with chemotherapy, in clinical trials assessing myeloprotection and anti-tumor efficacy endpoints in a variety of tumors including colorectal cancer (CRC), metastatic triple negative breast cancer (mTNBC), neoadjuvant breast cancer, non-small cell lung cancer (NSCLC) and bladder cancer. Its Rintodestrant, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive (ER+) breast cancer. Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. Its therapies are designed to improve outcomes for patients across multiple oncology indications.

• G1 THERAPEUTICS IN